Porton Pharma Solutions Ltd(300363) 3 announced on March 25 that benefiting from the continued high prosperity of cdmo industry, the company’s customer pipelines and product pipelines have been continuously expanded and enriched. In the first quarter of 2022, the company’s orders on hand increased strongly, and major orders received in the early stage were delivered successively. The company is expected to achieve an operating revenue of 1.357 billion yuan – 1.466 billion yuan, a year-on-year increase of 150% – 170%.
In addition, with the strong growth of operating revenue, Porton Pharma Solutions Ltd(300363) continues to improve its R & D technology capacity and delivery capacity. In the first quarter of 2022, the company is expected to realize a net profit of RMB 326344 million attributable to shareholders of listed companies, with a year-on-year increase of 270% – 290%; It is estimated that the net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses is 324 million yuan to 339 million yuan, with a year-on-year increase of 330% – 350%.
